Development Of Pretomanids And Their Therapeutic Uses In The Treatment Of Tuberculosis

Abstract

The most common infectious cause of death worldwide is tuberculosis (TB). Although new anti-tuberculosis medications have been
developed, controlling resistant Mycobacteria remains difficult. New drug development and targeted drug delivery techniques have the
potential to shorten treatment times, lessen side effects, and improve treatment outcomes. Pretomanid is the third drug authorised as a
component of a novel therapeutic regimen for treating drug-resistant TB, following bedaquiline and delamanid. It is one of the
promising medications that has the potential to change TB therapy and carry out the World Health Organization's End TB strategy.
Pretomanid's efficacy has been documented in numerous observational and clinical trials. The pretomanid-based regimen is advised
under an operational research framework, which forbids its wider and programmatic usage, although long-term safety data in humans
are still lacking. Before pretomanid can be hailed as a promising candidate treatment for different types of TB and certain patients, in
our opinion, further research must be done. Pretomanid development and its clinical use in the treatment of Mycobacterium tuberculosis
are updated in this study. Pretomanid is administered orally, 200 mg once day with food, along with bedaquiline (200 mg three times
weekly for 24 weeks after 400 mg once daily for two weeks), for a total of 26 weeks.